EFFICACY OF CO-ADMINISTRATION OF PANTOPRAZOLE SODIUM AND SOMATOSTATIN ON SEVERE ACUTE PANCREATITIS

Hongbin Jiao¹, Lei Jiao², Xueyan Bai³, Baojuan Han⁴, Xianliang Chen^{4, *}

¹Emergency Center, Xingtai People's Hospital, Xingtai, Hebei, 054001, China - ²Xingtai Medical College, Xingtai, Hebei, 054002, China - ³Intensive Care Unit, Xingtai People's Hospital, Xingtai, Hebei, 054001, China - ⁴Department of Gastrology, Xingtai People's Hospital, Xingtai, Hebei, 054001, China

Objective: This study aims to investigate the efficacy of co-administration of pantoprazole sodium and somatostatin on severe acute pancreatitis. 

Methods: In this hospital, we selected a total of 90 patients with severe acute pancreatitis between February 2018 and January 2019; then, we divided them into the control and observation groups. Patients in the control group took pantoprazole sodium, while the somatostatin and pantoprazole sodium were co-administrated for those in the observation group. Following medication, we compared the efficacy, remission time of abdominal pain, the recovery time of gastrointestinal tract function, remission time of ascites, weaning time of ventilator, levels of inflammatory indicators (TNF-α, IL-8, and hs-CRP) before and after treatment, Glasgow Coma Scale scores, APACHE II scores, and the adverse reactions, including pulmonary infection, acute respiratory distress syndrome, and pancreatic pseudocyst. 

Results: First and foremost, the total efficacy rate of patients in the observation group was significantly higher than that in the control group (P<0.05). Before the treatment, comparisons of the inflammatory indicators, Glasgow Coma Scale scores, and APACHE-II scores in patients of two groups presented no significant differences (P>0.05); however, significant changes were observed in these indicators after treatment (P<0.05). The treatment for patients in the observation group shortened the remission time of abdominal pain, the recovery time of gastrointestinal tract function, remission time of ascites, and weaning time of the ventilator significantly compared to their counterparts in the control group (P<0.05). However, patients in the observation group suffered less from the adverse reactions than those in the control group, with a lower incidence rate of some of such reactions, including pulmonary infection, acute respiratory distress syndrome, and pancreatic pseudocyst (P<0.05). 

Conclusion: Co-medication of pantoprazole sodium and somatostatin presents a promising outcome in the treatment of severe acute pancreatitis patients.